Alkermes Stops Reporting Avadel's Profit After Its $2.3 Billion Deal, Calling It Impracticable
The drugmaker's latest quarterly report says Avadel's stand-alone net income can no longer be presented, while LUMRYZ sales reached $226.0 million.
Alkermes, the Dublin-based drugmaker that develops medicines for brain and nervous system diseases, no longer shows what Avadel earns on its own. Its 10-Q quarterly report calls presenting Avadel's net income "impracticable" because the operations were folded in shortly after the February 12, 2026 closing.
From a stated profit to revenue only
The company says Avadel and Alkermes no longer operate as separate entities inside its organizational structure. The 10-Q gives only LUMRYZ revenue: $89.9 million for the third quarter and $226.0 million for the first nine months.
The prior quarterly filing had given Avadel's results: a $2.7 million net loss for the three months and $13.6 million of net income for six months, on revenue of $96.6 million and $136.1 million. LUMRYZ revenue was lower in the third quarter than the $96.6 million of the second.
In the earnings release issued the same day, Alkermes said about 4,100 patients were on LUMRYZ at the end of the quarter.
What the purchase left on the balance sheet
Alkermes paid total preliminary consideration of $2,306,920 thousand for Avadel. The balance sheet now carries $1,741.8 million of net intangibles, $592.5 million of goodwill and $136.9 million of contingent consideration.
The purchase price allocation is still preliminary, and the company expects to finish it no later than one year from the closing date. A contingent value right could pay former Avadel holders up to $165.7 million; the company expects that milestone to be determined by the end of 2027.
The deal's weight shows in earnings. Alkermes posted net income of $16.3 million for the third quarter but a nine-month net loss of $49.7 million, against $192.3 million of income a year earlier. Nine-month interest expense was $74.4 million, and $72.4 million of inventory step-up, a non-cash charge, ran through cost of goods.
Cheaper debt, with a cap on rates
Alkermes financed the deal with term loans. An August amendment cut the spread on the term loan A facility by 0.75 percentage points and on the term loan B facility by 0.50 percentage points.
In October it entered two zero-cost interest rate collars, each covering $375.0 million, with a Term SOFR cap of 5.25%. The company said they limit its exposure to swings in the benchmark rate on its variable-rate debt.
The CVR payout of up to $165.7 million depends on a milestone the company expects to be determined by the end of 2027.
Sources
- 10-Q Filing — Alkermes (ALKS) — SEC EDGAR
- 10-Q Filing — Alkermes (ALKS), Q2 FY2026 filed 2026-07-28 (comparison basis) — SEC EDGAR
- Earnings release (8-K Item 2.02, alks-ex99_1.htm) — Alkermes, filed 2026-11-03 — SEC EDGAR
- Alkermes: Q3 Earnings Snapshot — Associated Press
- Alkermes GAAP EPS of $0.09 beats by $0.15, revenue of $480.1M beats by $16.62M (ALKS:NASDAQ) — seekingalpha.com
- Alkermes: Q3 Earnings Snapshot | wusa9.com — Associated Press
- Alkermes: Q3 Earnings Snapshot | 9news.com — Associated Press
- Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In? — Yahoo Finance